Last updated on February 2018

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Brief description of study

BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.

Clinical Study Identifier: NCT02976493

Find a site near you

Start Over

Local Institution

Shinjuku-ku, Japan
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.